243 related articles for article (PubMed ID: 14750459)
1. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors.
Eaddy M; Bramley T; Regan T
Manag Care Interface; 2003 Dec; 16(12):22-7. PubMed ID: 14750459
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
[TBL] [Abstract][Full Text] [Related]
4. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
7. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
Sheehan DV; Eaddy MT; Shah MB; Mauch RP
Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
9. Adverse events after the abrupt discontinuation of paroxetine.
Dominguez RA; Goodnick PJ
Pharmacotherapy; 1995; 15(6):778-80. PubMed ID: 8602387
[TBL] [Abstract][Full Text] [Related]
10. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
Keene MS; Eaddy MT; Nelson WW; Sarnes MW
Am J Manag Care; 2005 Oct; 11(12 Suppl):S362-9. PubMed ID: 16236018
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in antidepressant drug response.
Keers R; Aitchison KJ
Int Rev Psychiatry; 2010; 22(5):485-500. PubMed ID: 21047161
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine in the treatment of generalised anxiety disorder.
Snyderman SH; Rynn MA; Bellew K; Rickels K
Expert Opin Pharmacother; 2004 Aug; 5(8):1799-806. PubMed ID: 15264994
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine: safety and tolerability issues.
Marks DM; Park MH; Ham BJ; Han C; Patkar AA; Masand PS; Pae CU
Expert Opin Drug Saf; 2008 Nov; 7(6):783-94. PubMed ID: 18983224
[TBL] [Abstract][Full Text] [Related]
14. New dosage-reduction regime to avoid paroxetine discontinuation syndrome.
Pacheco Yáñez L; Malo P; Etxebeste M; Aragües E; Medrano J
Can J Psychiatry; 2003 Mar; 48(2):129-30. PubMed ID: 12655918
[No Abstract] [Full Text] [Related]
15. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine: new drug. Adverse effects and no proven efficacy.
Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Baldwin DS; Huusom AK; Maehlum E
Br J Psychiatry; 2006 Sep; 189():264-72. PubMed ID: 16946363
[TBL] [Abstract][Full Text] [Related]
18. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
20. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
